A proteomic investigation into adriamycin chemo-resistance of human leukemia K562 cells.
This study aimed to explore the mechanism of adriamycin resistance in human chronic myelogenous leukemia cells. Proteomic approach was utilized to compare and identify differentially expressed proteins between human chronic myelogenous leukemia K562 cells and their adriamycin-resistant counterparts. The differentially expressed proteins were analyzed by 2-DE (two-dimensional gel electrophoresis), and protein identification were performed on ESI-Q-TOF MS/MS instrument. Out of the 35 differentially expressed proteins between the two cell lines, 29 were identified and grouped into 10 functional classes. Most of identified proteins were related to the categories of metabolism (24%), proteolysis (13%), signal transduction (21%) and calcium ion binding (6%), suggesting that alterations of those biological processes might be involved in adriamycin resistance of K562 cells. We believe this study may provide some clues to a better understanding of the molecular mechanisms underlying adriamycin resistance.
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu 610041, People's Republic of China.
Xingchen
X
Peng
Fengming
F
Gong
Gang
G
Xie
Yuwei
Y
Zhao
Minghai
M
Tang
Luoting
L
Yu
Aiping
A
Tong
D000970:Antineoplastic Agents / Q000494:pharmacology*; D015153:Blotting, Western; D004317:Doxorubicin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm; D015180:Electrophoresis, Gel, Two-Dimensional; D006801:Humans; D020014:K562 Cells; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000473:pathology*; D040901:Proteomics; D021241:Spectrometry, Mass, Electrospray Ionization
D000970:Antineoplastic Agents; D004317:Doxorubicin
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Electrophoresis. 2003 Jul;24(14):2386-404
12874874
Adv Pharmacol. 2009;57:91-135
20230760
Clin Cancer Res. 2003 Dec 15;9(17):6316-25
14695130
Cancer Lett. 2003 May 30;195(1):1-16
12767506
Gen Pharmacol. 1995 Dec;26(8):1773-84
8745168
Electrophoresis. 2000 Aug;21(14):3048-57
11001322
Clin Cancer Res. 2002 Apr;8(4):1068-74
11948115
Cancer Chemother Pharmacol. 2008 Apr;61(5):791-802
17593366
Cancer Res. 2005 Jul 15;65(14):6054-62
16024605
Oncogene. 2001 Oct 25;20(48):7128-33
11704839
Expert Rev Proteomics. 2004 Dec;1(4):493-501
15966844
Proteomics. 2001 Oct;1(10):1233-48
11721635
Int J Cancer. 2009 Nov 15;125(10):2316-22
19598262
Int J Oncol. 2003 May;22(5):1057-64
12684672
Clin Cancer Res. 2003 Mar;9(3):1136-44
12631619
J Proteome Res. 2009 Nov;8(11):5041-7
19764771
Proteomics. 2003 Oct;3(10):1988-2001
14625861
Cell Signal. 1999 Aug;11(8):545-54
10433515
Eur J Cancer. 2004 Mar;40(4):594-605
14962729
Cancer. 2003 Mar 15;97(6):1573-81
12627523
J Cancer Res Clin Oncol. 2009 Feb;135(2):181-9
18758817
OMICS. 2009 Dec;13(6):467-76
20001861
J Mol Biol. 2001 Jan 5;305(1):121-35
11114252
Eur J Cancer. 2007 May;43(7):1125-33
17379504
Mol Cell Proteomics. 2005 Apr;4(4):523-33
15684406
Oncogene. 2004 Apr 12;23(16):2934-49
15077155
Clin Chem Lab Med. 2002 Mar;40(3):221-34
12005211
Cancer Metastasis Rev. 1994 Jun;13(2):139-68
7923547
Biochim Biophys Acta. 2008 Sep;1784(9):1184-91
18503785
Cancer Res. 1999 Dec 1;59(23):5863-70
10606224
Genes Dev. 1999 Mar 1;13(5):505-10
10072378
Gastric Cancer. 2004;7(3):160-6
15449204
Biochem Biophys Res Commun. 1998 Apr 28;245(3):641-5
9588168
Gastroenterology. 2005 Oct;129(4):1187-97
16230073
Oncogene. 1990 Sep;5(9):1321-8
2120668
Nat Rev Cancer. 2004 May;4(5):349-60
15122206
J Natl Cancer Inst. 2001 Feb 21;93(4):266-76
11181773